Our drug products are tailor made to target specific cannabinoid receptors in the human body. To facilitate our ambitions, we have state-of-the-art laboratories with advanced analytical technologies. Activities from basic- to applied research play an important role in ensuring we are at the forefront of developing proprietary drug delivery systems subject to clinical testing and ultimately market authorization.

Research and development (R&D) is a key area of focus for Tetra Pharm Technologies as we continue to address unmet needs in chronic pain and mental disorders. Our multidisciplinary R&D team is constantly pushing the boundaries of science to develop novel formulation technologies for delivery of molecules targeting the endocannabinoid system. So-called enabling technologies are required to facilitate the delivery of poorly water-soluble compounds like cannabinoids and related molecules (active ingredients).

We currently have several lead compounds indicated for pain and mental health disorders in our pipeline, and we expect to initiate clinical trials on at least two in early 2024.

We consider a strong professional network as key to the advancement of science and innovation. Therefore, we are constantly in close dialogue with world leading researchers and healthcare professionals in the field of mental disorders and chronic pain.